Literature DB >> 14507110

Increased fibrin polymerization rate in patients with primary antiphospholipid syndrome and systemic lupus erythematosus.

Paola de Pablo1, Alvaro Ramírez, Evelyn Cortina, Aurora de la Peña, José Zamora, Raúl Izaguirre, Mary-Carmen Amigo.   

Abstract

The main event in blood coagulation is the thrombincatalyzed conversion of fibrinogen into fibrin. This singular transformation of a soluble protein into an insoluble polymeric network occurs with faultless precision. Abnormalities of fibrin polymerization can lead to hemorragic and thrombotic disorders. Increased fibrinogen plasma concentration (Fg) and fibrin polymerization rate (FPR) could be additional risk factors associated with atherothrombosis in antiphospholipid syndrome (APS) and in systemic lupus erythematosus (SLE). Our objective was to investigate Fg and FPR in consecutive patients with APS and SLE. Thirty-nine patients and 31 age- and gender-matched healthy controls were studied. Sixteen patients had primary APS, 13 patients had SLE, and 10 patients had SLE plus APS. The mean of the FPR was significantly increased (0.2799 +/- 0.091) in patients with APS plus SLE as compared with the control group (0.2052 +/- 0.055) (p < 0.05). Fg was higher in APS plus SLE (3.15 g/L +/- 0.43) and in primary APS (3.03 g/L +/- 0.29) than in controls (2.87 g/L +/- 0.49). Our results demonstrated an increased FPR in patients with APS plus SLE. This phenomenon could be an additional risk factor for thrombosis in these autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14507110     DOI: 10.1177/107602960300900306

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Combined protein- and nucleic acid-level effects of rs1143679 (R77H), a lupus-predisposing variant within ITGAM.

Authors:  Amit K Maiti; Xana Kim-Howard; Prasenjeet Motghare; Vandana Pradhan; Kek Heng Chua; Celi Sun; María Teresa Arango-Guerrero; Kanjaksha Ghosh; Timothy B Niewold; John B Harley; Juan-Manual Anaya; Loren L Looger; Swapan K Nath
Journal:  Hum Mol Genet       Date:  2014-03-07       Impact factor: 6.150

2.  Use of serum or buffer-changed EDTA-plasma in a rapid, inexpensive, and easy-to-perform hemolytic complement assay for differential diagnosis of systemic lupus erythematosus and monitoring of patients with the disease.

Authors:  Kristina N Ekdahl; Dan Norberg; Anders A Bengtsson; Gunnar Sturfelt; Ulf R Nilsson; Bo Nilsson
Journal:  Clin Vaccine Immunol       Date:  2007-03-07

3.  Contact activation products are new potential biomarkers to evaluate the risk of thrombotic events in systemic lupus erythematosus.

Authors:  Jennie Bäck; Christian Lood; Anders A Bengtsson; Kristina Nilsson Ekdahl; Bo Nilsson
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

4.  Lytic Susceptibility, Structure, and Mechanical Properties of Fibrin in Systemic Lupus Erythematosus.

Authors:  Rustem I Litvinov; Rosa M Nabiullina; Laily D Zubairova; Mileusha A Shakurova; Izabella A Andrianova; John W Weisel
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

5.  Proteins Involved in the Induction of Procoagulant Activity and Autoimmune Response in Patients With Primary Antiphospholipid Syndrome.

Authors:  Débora Medeiros Araújo; Carlos Ewerton Maia Rodrigues; Nidyedja Goyanna Gomes Gonçalves; Carlos Nobre Rabelo-Júnior; Marina Duarte Pinto Lobo; Renato de Azevedo Moreira; Ana Cristina de Oliveira Monteiro-Moreira
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.